Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR1 | P32246 | 2/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA1 | P00915 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.36 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.36 |
| ▸ | CHKA | P35790 | 1/20 | 0.35 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.34 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.34 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.34 |
| ▸ | CHRNB3 | Q05901 | 1/20 | 0.34 |
| ▸ | CHRNA6 | Q15825 | 1/20 | 0.34 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | RRM1 | P23921 | 1/20 | 0.31 |
| ▸ | RRM2 | P31350 | 1/20 | 0.31 |
| ▸ | RRM2B | Q7LG56 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4975517 | 0.84 | PLD1 (0.37) | CCR1 | |
| SCHEMBL16602550 | 0.84 | CCR1 (0.41) | CCR1HPGDRRM1RRM2RRM2B | |
| SCHEMBL27154468 | 0.77 | CHRM5 (0.42) | HPGDCA2CA12CA1CA9 | |
| SCHEMBL27154469 | 0.77 | CHRM5 (0.42) | HPGDCA2CA12CA1CA9 | |
| SCHEMBL6015101 | 0.76 | CCR1 (0.42) | CCR1CNR2 | |
| SCHEMBL3321981 | 0.74 | CCR1 (0.48) | CCR1 | |
| SCHEMBL6015115 | 0.73 | L3MBTL3 (0.43) | CCR1CHRM3SIGMAR1POLB | |
| SCHEMBL30232419 | 0.73 | HPGD (0.44) | HPGDCA2CA12CA1CA9 | |
| SCHEMBL15203528 | 0.71 | CTSS (0.38) | CCR1CNR2 | |
| SCHEMBL15254954 | 0.71 | CCR1 (0.41) | CCR1CHRM5CHRM3POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080318945-A1 | Novel Compounds | CASILLAS LINDA N | 2008-12-25 | — | — | US | disclosed |
| EP-1968590-A2 | NOVEL COMPOUNDS | SmithKline Beecham Corporation (US) | 2008-09-17 | — | — | EP | disclosed |
| WO-2007070865-A2 | PIPERAZINE COMPOUNDS AS AGONISTS OF TRPV4 CHANNEL RECEPTORS | SMITHKLINE BEECHAM CORPORATION (US) | 2007-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080318945-A1 | Novel Compounds | TRPV4, TRPV1, TRPV3 | CCR1 919/4885HPGD 1915/4885CA2 520/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.